MA26990A1 - Procedes d'identification de composes pour reguler la masse ou la fonction musculaire utilisant des recepteurs de facteur de liberation de la corticotropine. - Google Patents

Procedes d'identification de composes pour reguler la masse ou la fonction musculaire utilisant des recepteurs de facteur de liberation de la corticotropine.

Info

Publication number
MA26990A1
MA26990A1 MA27267A MA27267A MA26990A1 MA 26990 A1 MA26990 A1 MA 26990A1 MA 27267 A MA27267 A MA 27267A MA 27267 A MA27267 A MA 27267A MA 26990 A1 MA26990 A1 MA 26990A1
Authority
MA
Morocco
Prior art keywords
crf2r
methods
mass
function
corticotropin
Prior art date
Application number
MA27267A
Other languages
English (en)
Inventor
Robert Joseph Isfort
Russell James Sheldon
Original Assignee
Procter & Gamble
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Procter & Gamble filed Critical Procter & Gamble
Publication of MA26990A1 publication Critical patent/MA26990A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/0004—Screening or testing of compounds for diagnosis of disorders, assessment of conditions, e.g. renal clearance, gastric emptying, testing for diabetes, allergy, rheuma, pancreas functions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/02—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2869—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against hormone receptors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/566—Immunoassay; Biospecific binding assay; Materials therefor using specific carrier or receptor proteins as ligand binding reagents where possible specific carrier or receptor proteins are classified with their target compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/72—Assays involving receptors, cell surface antigens or cell surface determinants for hormones
    • G01N2333/726—G protein coupled receptor, e.g. TSHR-thyrotropin-receptor, LH/hCG receptor, FSH
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/10—Screening for compounds of potential therapeutic value involving cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Endocrinology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biochemistry (AREA)
  • Pathology (AREA)
  • Hematology (AREA)
  • Neurology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Toxicology (AREA)
  • Biophysics (AREA)
  • Cell Biology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • General Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)

Abstract

PROCEDES POUR IDENTIFIER DES COMPOSES POUR REGULER LA MASSE OU LA FONCTION MUSCULAIRE EN UTILISANT DES RECEPTEURS DE FACTEURS LIBERATEURS DE CORTICOTROPINE THE PROCTER & GAMBLE COMPANY Invention de : ISFORT Robert SHELDON Russell Priorité : demande de brevet déposée aux Etats-Unis le 6 mars 2001 sous le no. 09/799,978 Procédés de criblage pour identifier des composés qui se lient à des récepteurs de facteurs 2 libérant de la corticotropine (CRF2R) ou activent ceux-ci et régulent ou régulent potentiellement la masse ou la fonction des muscles squelettiques in vivo. On décrit également des procédés de criblage pour identifier des composés qui prolongent ou augmentent l'activation des CRF2R ou de trajets de transduction de signaux des CRF2R, augmentent les CRF2R ou augmentent l'expression des CRF. On décrit également des compositions pharmaceutiques comprenant des agonistes de CRF2R, des anticorps aux CRF2R et des procédés permettant d'augmenter la masse ou la fonction des muscles squelettiques ou pour le traitement de l'atrophie des muscles squelettiques en utilisant des CRF2R comme cible pour l'intervention et des procédés de traitement de dystrophies usculaires.
MA27267A 2001-03-06 2003-08-07 Procedes d'identification de composes pour reguler la masse ou la fonction musculaire utilisant des recepteurs de facteur de liberation de la corticotropine. MA26990A1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US09/799,978 US6670140B2 (en) 2001-03-06 2001-03-06 Methods for identifying compounds for regulating muscle mass or function using corticotropin releasing factor receptors

Publications (1)

Publication Number Publication Date
MA26990A1 true MA26990A1 (fr) 2004-12-20

Family

ID=25177205

Family Applications (1)

Application Number Title Priority Date Filing Date
MA27267A MA26990A1 (fr) 2001-03-06 2003-08-07 Procedes d'identification de composes pour reguler la masse ou la fonction musculaire utilisant des recepteurs de facteur de liberation de la corticotropine.

Country Status (28)

Country Link
US (3) US6670140B2 (fr)
EP (1) EP1379873B1 (fr)
JP (2) JP4331942B2 (fr)
KR (2) KR100596991B1 (fr)
CN (1) CN100520408C (fr)
AR (1) AR032957A1 (fr)
AT (1) ATE429242T1 (fr)
AU (1) AU2002303121B2 (fr)
BR (1) BR0207881A (fr)
CA (1) CA2439170C (fr)
CZ (1) CZ20032395A3 (fr)
DE (1) DE60232063D1 (fr)
ES (1) ES2325485T3 (fr)
HU (1) HUP0402173A2 (fr)
IL (1) IL157330A0 (fr)
MA (1) MA26990A1 (fr)
MX (1) MXPA03008114A (fr)
MY (1) MY134755A (fr)
NO (1) NO20033936L (fr)
NZ (1) NZ527124A (fr)
PE (1) PE20020993A1 (fr)
PL (1) PL367187A1 (fr)
RU (1) RU2260805C2 (fr)
SA (1) SA02230159B1 (fr)
SK (1) SK12132003A3 (fr)
TW (1) TWI227780B (fr)
WO (1) WO2002069908A2 (fr)
ZA (1) ZA200305642B (fr)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1484650B (zh) * 2000-08-04 2012-12-12 研究发展基金会 尿皮质素蛋白及其用途
WO2002024732A2 (fr) * 2000-09-22 2002-03-28 Max-Planck-Gesellschaft Zur Förderung Der Wissenschaften Methodes permettant d'ameliorer les proprietes antagonistes/agonistes des antagonistes/agonistes peptidiques du recepteur de la corticoliberine (crfr)
US6670140B2 (en) * 2001-03-06 2003-12-30 The Procter & Gamble Company Methods for identifying compounds for regulating muscle mass or function using corticotropin releasing factor receptors
US7192923B2 (en) * 2002-01-16 2007-03-20 The Procter & Gamble Company Corticotropin releasing factor 2 receptor agonists
WO2007090087A2 (fr) * 2006-01-27 2007-08-09 Research Development Foundation Inhibiteurs du recepteur 2 du facteur de liberation de la corticotrophine et ses utilisations
US7982018B2 (en) * 2006-10-16 2011-07-19 Conjuchem, Llc Modified corticotropin releasing factor peptides and uses thereof
GB0624282D0 (en) * 2006-12-05 2007-01-10 Cavalla David Treatment of cachexia
CA2687908A1 (fr) * 2007-05-23 2008-12-04 Pharmacome Llc Recepteur conjugue aux proteines g presentant une modification de l'affinite pour son ligand et son utilisation
WO2010036918A2 (fr) * 2008-09-26 2010-04-01 University Of Massachusetts Récepteur intracellulaire d'adn
EP2654461B1 (fr) * 2010-12-23 2018-04-11 Amazentis SA Compositions et procédés pour traiter des troubles metaboliques
JP6177249B2 (ja) * 2011-11-14 2017-08-09 リジェネロン・ファーマシューティカルズ・インコーポレイテッドＲｅｇｅｎｅｒｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． Ｇｄｆ８及び／又はアクチビンａに特異的に拮抗することによって筋肉量及び筋力を増加させる組成物及び方法
RU2517259C1 (ru) * 2013-03-06 2014-05-27 Федеральное государственное бюджетное учреждение науки Государственный научный центр Российской Федерации - Институт медико-биологических проблем Российской академии наук (ГНЦ РФ-ИМБП РАН) Способ профилактики и снижения деструкции белков скелетных мышц при их атрофии, вызванной гипокинезией и/или гравитационной разгрузкой
JP2015071549A (ja) * 2013-10-02 2015-04-16 株式会社ファンケル アトロジン−１抑制剤
RU2568903C2 (ru) * 2014-04-07 2015-11-20 Государственное бюджетное образовательное учреждение высшего профессионального образования "Алтайский государственный медицинский университет" Министерства здравоохранения Российской Федерации Способ оценки анаболического действия лекарственных препаратов
WO2016168613A1 (fr) 2015-04-15 2016-10-20 Regeneron Pharmaceuticals, Inc. Méthode pour augmenter la résistance et la fonctionnalité avec des inhibiteurs de gdf-8
JP2019533021A (ja) * 2016-10-20 2019-11-14 コーティーン インコーポレイテッド 不適応のストレス応答に寄与する疾患を処置する方法
KR20200128125A (ko) 2018-03-01 2020-11-11 리제너론 파아마슈티컬스, 인크. 신체 조성을 변경하기 위한 방법
CN119746078B (zh) * 2025-03-04 2025-05-30 华中科技大学 一种参与396,404位点丝氨酸磷酸化tau蛋白聚集mRNA的筛选方法及其应用

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4415558A (en) * 1981-06-08 1983-11-15 The Salk Institute For Biological Studies CRF And analogs
US4533654A (en) * 1982-09-29 1985-08-06 The Salk Institute For Biological Studies Urotensin peptides
US4489163A (en) * 1983-04-14 1984-12-18 The Salk Institute For Biological Studies rCRF and analogs
US4605642A (en) * 1984-02-23 1986-08-12 The Salk Institute For Biological Studies CRF antagonists
US4594329A (en) * 1984-05-14 1986-06-10 The Salk Institute For Biological Studies CRF analogs
US4801612A (en) * 1986-07-03 1989-01-31 Regents Of The University Of California Method of inhibiting inflammatory response
DE3703340A1 (de) * 1987-02-04 1988-08-18 Dirck Dr Med Oppermann Pharmazeutische zubereitung zur behandlung der herzinsuffizienz
US4908352A (en) * 1987-09-28 1990-03-13 The Salk Institute For Biological Studies Urotensin peptides
US5109111A (en) * 1988-09-23 1992-04-28 The Salk Institute For Biological Studies CRF antagonists
US5278146A (en) * 1988-09-30 1994-01-11 The Salk Institute For Biological Studies CRF analogs
CA1340964C (fr) * 1988-09-30 2000-04-18 Jean E. F. Rivier Analogues du crf
US5235036A (en) * 1991-05-31 1993-08-10 The Salk Institute For Biological Studies Crf analogs
US5493006A (en) * 1993-06-16 1996-02-20 The Salk Institute For Biological Studies Cyclic CRF analogs
US6495343B1 (en) * 1993-06-18 2002-12-17 The Salk Institute For Biological Studies Cloning and recombinant production of CRF receptor(s)
US5728545A (en) * 1993-06-18 1998-03-17 The Salk Institute Of Biological Studies Cloning and recombinant production of CRF receptor (S)
EP0860501A3 (fr) 1994-06-14 1999-05-19 Neurocrine Biosciences, Inc. Récepteurs du facteur 2 libérant la corticotropine
CA2193072A1 (fr) * 1994-06-14 1995-12-21 Derek Chalmers Recepteurs du facteur2 liberant la corticotropine
US5786203A (en) * 1994-06-14 1998-07-28 Neurocrine Biosciences, Inc. Isolated nucleic acid encoding corticotropin-releasing factor2 receptors
US5663292A (en) 1994-12-12 1997-09-02 The Salk Institute For Biological Studies Cyclic CRF analogs
US5824771A (en) 1994-12-12 1998-10-20 The Salk Institute For Biological Studies Cyclic CRF agonists
US5660824A (en) 1995-05-24 1997-08-26 Grabstein; Kenneth H. Muscle trophic factor
EP0845035A2 (fr) 1995-06-13 1998-06-03 The Salk Institute For Biological Studies Peptides d'urocortine
US5869450A (en) 1996-03-06 1999-02-09 The Regents Of The University Of California Anti-inflammatory compositions and method with corticotropin-releasing factor analogs
US5888811A (en) * 1996-05-23 1999-03-30 Dupont Pharmaceuticals Company Corticotropin-releasing hormone receptor
CN1203061C (zh) * 1997-03-25 2005-05-25 艾弗拉药品公司 取代异喹啉类，其制备方法，药物组合物及其制药用途
US6846803B1 (en) * 1998-07-24 2005-01-25 Max Planck Gesellschaft Zur Forderung Der Wissenschaften E.V. Antagonists specific for the corticotropin-releasing factor receptor type 2 (CRFR2)
CN1484650B (zh) * 2000-08-04 2012-12-12 研究发展基金会 尿皮质素蛋白及其用途
US6670140B2 (en) * 2001-03-06 2003-12-30 The Procter & Gamble Company Methods for identifying compounds for regulating muscle mass or function using corticotropin releasing factor receptors

Also Published As

Publication number Publication date
AU2002303121B2 (en) 2005-11-10
CN100520408C (zh) 2009-07-29
ES2325485T3 (es) 2009-09-07
NO20033936D0 (no) 2003-09-05
US20040101911A1 (en) 2004-05-27
AR032957A1 (es) 2003-12-03
KR20060029704A (ko) 2006-04-06
EP1379873A2 (fr) 2004-01-14
US20060198842A1 (en) 2006-09-07
US7063954B2 (en) 2006-06-20
HUP0402173A2 (hu) 2005-01-28
JP2009029816A (ja) 2009-02-12
RU2260805C2 (ru) 2005-09-20
WO2002069908A2 (fr) 2002-09-12
PE20020993A1 (es) 2002-12-20
NZ527124A (en) 2005-11-25
US20030165807A1 (en) 2003-09-04
MY134755A (en) 2007-12-31
IL157330A0 (en) 2004-02-19
KR20030086289A (ko) 2003-11-07
JP2004532394A (ja) 2004-10-21
PL367187A1 (en) 2005-02-21
EP1379873B1 (fr) 2009-04-22
US7572768B2 (en) 2009-08-11
TWI227780B (en) 2005-02-11
ZA200305642B (en) 2004-06-22
WO2002069908A3 (fr) 2003-03-20
CN1820200A (zh) 2006-08-16
NO20033936L (no) 2003-11-05
BR0207881A (pt) 2005-08-30
SK12132003A3 (sk) 2004-05-04
CA2439170C (fr) 2011-05-10
DE60232063D1 (de) 2009-06-04
ATE429242T1 (de) 2009-05-15
CZ20032395A3 (cs) 2004-01-14
RU2003129500A (ru) 2005-03-10
CA2439170A1 (fr) 2002-09-12
JP4331942B2 (ja) 2009-09-16
KR100598441B1 (ko) 2006-07-10
KR100596991B1 (ko) 2006-07-07
SA02230159B1 (ar) 2007-05-06
US6670140B2 (en) 2003-12-30
EP1379873A4 (fr) 2006-03-22
MXPA03008114A (es) 2003-12-12

Similar Documents

Publication Publication Date Title
Boie et al. Cloning and expression of a cDNA for the human prostanoid IP receptor.
NO20022655D0 (no) <Beta>-2-adrenerge reseptoragonister
Van Beneden et al. Expression of Ly49E and CD94/NKG2 on fetal and adult NK cells
WO2002069908A3 (fr) Procedes d'identification de composes permettant de reguler la masse ou la fonction musculaire au moyen de recepteurs de la corticoliberine
EP1308461A3 (fr) Anticorps contre des bèta-amyloides ou leurs dérivés, et leurs utilisations
BG109311A (en) PHARMACEUTICAL COMPOSITION, INCLUDING HUMAN ANTIBODIES CONNECTING HUMAN TNFAL, AND HIS APPLICATION
MA30555B1 (fr) Procedes d'utilisation du recepteur gpr119 pour identifier des composes utiles pour augmenter la masse osseuse chez un individu
WO2002085285A3 (fr) Methodes et compositions permettant de reguler la formation osseuse et cartilagineuse
ATE275562T1 (de) Neue form vom irbesartan, verfahren um diese form zu erhalten und sie enthaltende pharmazeutische zusammensetzungen
WO1998058911A3 (fr) Agonistes de prostaglandines
ATE396969T1 (de) 3,6-disubstituierte azabicyclo (3.1.0)hexanderivate, die sich als muscarinrezeptorantagonisten eignen
AU5174000A (en) Pro-fragrances
EP0801049A3 (fr) Dérivés de cyclopentanebutanol comme matières odorantes
Mary et al. Modulation of T cell activation by differential regulation of the phosphorylation of two cytosolic proteins: implication of both Ca2+ and cyclic AMP-dependent protein kinases
MA27991A1 (fr) Derives d'aminoquinoline et leur utilisation comme ligands d'adenosine a3
WO2000002582A3 (fr) Traitement de la maladie coeliaque a l'aide d'antagonistes de l'interleukine-15
Légrádi et al. Lysophosphatidylcholine is a regulator of tyrosine kinase activity and intracellular Ca2+ level in Jurkat T cell line
Fujii et al. YM905, a novel M3 antagonist, inhibits Ca2+ signaling and c-fos gene expression mediated via muscarinic receptors in human T cells
WO2004008153A3 (fr) Diagnostique et therapie des maladies associees au recepteur presume de neurotransmetteurs chez l'humain (pnr)
WO2003104761A3 (fr) Mesure de peptides de melanocortine et utilisations correspondantes
ATE222901T1 (de) Carboxylsubstituierte chromanderivate zur verwendung als beta 3 adrenorezeptor-agonisten
MX9703232A (es) Nuevos antagonistas del receptor muscarinico.
ATE211754T1 (de) Gleitmittel auf basis von octadecan
WO2005017484A3 (fr) Methodes d'identification de composes permettant de reguler la masse ou la fonction musculaire utilisant des recepteurs de la dopamine
MA31061B1 (fr) Inhibiteurs de kinases.